CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Launched by COREVITAS · Aug 19, 2024

Keywords

ClinConnect Summary

The CorEvitas International Adolescent Alopecia Areata Drug Safety and Effectiveness Registry is a study aimed at understanding the safety and effectiveness of treatments for severe alopecia areata, a condition that causes hair loss. This registry will observe adolescents aged 12 to 17 who have been diagnosed with severe alopecia areata and are receiving regular care from dermatologists. Participants will be included if they are starting a new medication for their condition, either advanced therapies or traditional systemic treatments, and if their doctor believes they are suitable candidates for these treatments.

If eligible, participants can expect to visit their healthcare provider according to their regular schedule. These visits will help monitor their treatment and overall health. It’s important to note that the study is currently recruiting participants, and those who have been part of other blinded clinical trials or who cannot provide height measurements will not be eligible. This research aims to gather valuable information that could improve future treatments for adolescents with severe alopecia areata.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• To be eligible to participate in this registry, an individual must meet all the following criteria:
• • 1. Has ever been diagnosed with severe AA by a dermatologist or a qualified dermatology provider.
• • 2. Is 12-17 years of age at the time of enrollment.
• • 3. Is willing to provide consent/assent for participation in the registry.
• • 4. Has been prescribed a new commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents in the context of routine clinical care that is consistent with local prescribing guidelines and/or regulations for the country where the site is located.
• • A new therapy is a medication that the subject has never taken before.
• • 1. At the time of registry enrollment OR
• • 2. Within 6 months prior to registry enrollment In the opinion of the treating provider, is deemed a candidate for treatment with a commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents but has not received nor is planning to initiate treatment at the time of registry enrollment.
• Exclusion Criteria:
• An individual who meets any of the following criteria will be excluded from participation in the registry:
• • 1. Is participating or planning to participate in a blinded clinical trial for any investigational medication.
• • 2. Is unwilling or unable to provide standing height measurements.